Advertisement
Research Article Free access | 10.1172/JCI118415
Department of Medicine, Novum, Karolinska Institute at Huddinge University Hospital, Sweden.
Find articles by Rudling, M. in: JCI | PubMed | Google Scholar
Department of Medicine, Novum, Karolinska Institute at Huddinge University Hospital, Sweden.
Find articles by Olivecrona, H. in: JCI | PubMed | Google Scholar
Department of Medicine, Novum, Karolinska Institute at Huddinge University Hospital, Sweden.
Find articles by Eggertsen, G. in: JCI | PubMed | Google Scholar
Department of Medicine, Novum, Karolinska Institute at Huddinge University Hospital, Sweden.
Find articles by Angelin, B. in: JCI | PubMed | Google Scholar
Published January 15, 1996 - More info
Growth hormone (GH) has an important role in the regulation of hepatic LDL receptor expression and plasma lipoprotein levels. This investigation was undertaken to evaluate if these effects of GH on hepatic LDL receptors are direct or mediated by insulin-like growth factor I (IGF-I). Two models were studied in which substitution with GH is important for the regulation of hepatic LDL receptors: hypophysectomized rats receiving high-dose ethynylestradiol or challenge with dietary cholesterol. The hypophysectomized rats were hormonally substituted by infusion with dexamethasone and L-thyroxine, and either GH or IGF-I. In both models, GH was essential for maintaining normal expression of LDL receptors. In contrast, despite fully normalized plasma levels, IGF-I did not support the expression of hepatic LDL receptors. Analysis of plasma lipoproteins revealed that substitution with GH, but not with IGF-I, reduced LDL and intermediate density lipoproteins. In addition, determination of hepatic mRNA levels for apo B-100 and apo B-48 indicated that GH may be more effective than IGF-I in the promotion of apo B mRNA editing. In conclusion, GH has specific effects on hepatic LDL receptor expression and plasma lipoprotein levels that are not mediated by IGF-I.